Two-year outcomes following PSMA PET and MRI guided prostate SABR with simultaneous focal boost: a brief report from the ARGOS-CLIMBER phase 1/2 trial.
Yasir Alayed, Andrew Loblaw, Lucas C Mendez et al.
✦ AI-curated · Sources linked
In 30 seconds
This brief report presents two-year outcomes from ARGOS-CLIMBER, a phase 1/2 clinical trial of PSMA PET- and MRI-guided stereotactic ablative radiotherapy (SABR) with simultaneous boosts to intraprostatic and nodal disease. The study enrolled men with unfavourable intermediate- or high-risk prostate cancer. The updated results describe acceptable safety and quality of life, alongside high biochemical and imaging response rates. The abstract does not provide numerical response rates or other quantitative outcome estimates.
Key findings
- Updated two-year results indicated acceptable safety and quality of life.
- Biochemical and imaging response rates were described as high, without numerical estimates in the abstract.
Why it matters
The report provides early follow-up on a PET- and MRI-guided radiotherapy approach that targets prostate and nodal disease with simultaneous boosts. Safety, quality of life, and biochemical and imaging responses are relevant outcomes when assessing this strategy, although the abstract’s qualitative reporting limits comparison with other treatment approaches.
What to keep in mind
The abstract provides no sample size or numerical outcome estimates, and reports only two-year outcomes from a phase 1/2 trial.